FDA adds rare eye-risk warning to GLP-1 labels
The FDA has ordered GLP-1 drug makers to warn on labels about a possible rare eye condition linked to lasting vision loss. The agency says the evidence is limited, but advises patients with new vision symptoms to seek care immediately.